NCT04963413View on ClinicalTrials.gov

RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.

PHASE1TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 13, 2022

Primary Completion Date

September 28, 2023

Study Completion Date

September 28, 2023

Conditions
Glioblastoma
Interventions
BIOLOGICAL

Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF

Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF

Trial Locations (1)

32610

University of Florida Health Shands Hospital, Gainesville

Sponsors
All Listed Sponsors
collaborator

Immunomic Therapeutics, Inc.

INDUSTRY

lead

University of Florida

OTHER